Compare Dollar General Corp. (DG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Summit Therapeutics Inc — how do they compare? Dollar General Corp. trades at $119.81 (market cap $26.49B), while Summit Therapeutics Inc trades at $15.27 (market cap $12.06B). The key difference: Dollar General Corp. is far larger — about 2.2× Summit Therapeutics Inc's market cap, and Dollar General Corp. pays a 1.97% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DG | SMMT | |
|---|---|---|
Market Cap | $26.49B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $26.98 |
52-Week Low | $95.94 | $12.55 |
Enterprise Value | $40.93B | $11.39B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $119.40, down 2.44% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, while consistently beating earnings expectations in recent quarters. Revenue growth continues with $40.61B in 2025, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Analyst consensus remains positive with 52% buy ratings and a $128.45 price target, representing 7.6% upside potential.
DG presents a compelling value opportunity with reasonable valuation metrics and consistent earnings beats, though margin compression and competitive pressures pose risks. The stock's current price near support levels combined with positive analyst sentiment suggests potential for recovery, but investors should monitor margin trends and competitive dynamics in the discount retail sector.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
